NVS - Marker Therapeutics: A Safer And Potentially More Effective CAR-T Alternative

Marker Therapeutics, is an immunotherapy innovator bringing an antigen-sensitized T cell product to market in a number of different cancer indications. The company is the product of a merger between TapImmune and Marker Therapeutics that completed on Oct 17th, 2018 and on Thursday, October 18th begins trading under ticker (MKMR), retiring TapImmune's ticker (TPIV). While the company is still early stage, the combined entity now offers a valuable pipeline of differentiated immunotherapies that, if successfully brought to market, could realize the dream of optimally utilizing the immune system to both fight cancer and prevent relapse